WELCOME

JPEO-CBD Medical Virtual Industry Day

https://connect.dco.dod.mil/jpeocbdvid

15 November 2012

UNCLASSIFIED

Joint Program Executive Office for Chemical and Biological Defense Medical Virtual Industry Day

Joint Program Executive Office for Chemical and Biological Defense

Joint Project Manager Transformational Medical Technologies (TMT) Overview

Mr. David Hough
Joint Project Manager
Transformational Medical Technologies
703.704.2374

November 15, 2012

Distribution Statement A: Approved for public release; distribution is unlimited.

Disclaimer

- **While we are presenting our currently planned business opportunities, we recognize that these may change given our changing fiscal environment and the strategic guidance of the Department of the Defense.**

- **New starts and increases to production levels in FY13 will be delayed until the Appropriations Bill is passed.**

JPM-TMT Organizational Structure

MR DAVID HOUGH
Joint Project Manager, TMT

JOHN GORRELL
Deputy JPM-TMT

LTC DAVID GIBSON
EID

DAVID KLAASSE
HFV

JPM-TMT Mission

MISSION:

Provide the Warfighter and the Nation with innovative medical solutions to protect against and treat emerging, genetically engineered, or unknown biothreats

Biological Defense Medical Products

JOINT PROJECT MANAGER TRANSFORMATIONAL MEDICAL TECHNOLOGIES

Protecting the Warfighter and the Nation from Biothreats

Advanced Development and Acquisition Programs

Capabilities

Supporting Science & Technology Efforts

SCIENCE & TECHNOLOGY		ADVANCED DEVELOPMENT
Development of additional broad-spectrum MCM against naturally occurring and/or engineered EID threats	1	MCM Development Against Emerging Infectious Diseases
Development of new therapeutic animal model systems for Emerging Diseases	2	
Manufacturing Scale Up of phosphorodiamidate morpholino (PMO) based MCMs	3	
Development of Animal Models for an Aerosol route of exposure label indication	4	
Reformulation of nucleotide based therapeutics for non-IV delivery	5	MCM Development Against Hemorrhagic Fever Viruses
Development of new therapeutic animal model systems for Hemorrhagic Fever Viruses	6	
Development of systems for early detection of virus in blood of animal models of infection	7	

Interagency & International Partners



Business Opportunities

1. HFV Class
   - FY 14/15 – Backfill pipeline with candidates for advanced development
   - Target all HFV Class beyond HFV *Filovirus* family
   - Potential other HFV family targets include *Arenavirus* and *Bunyavirus*
2. Emerging Infectious Diseases
   - FY14/15 – Evaluate spectrum of therapeutic response of current influenza drug candidate, *Favipiravir* (T-705) to diseases other than influenza
   - Potential future programs include new therapeutic model systems for other Emerging Diseases
3. Animal Models
   - Collaborate with FDA to qualify animal models that simulate human disease progression in laboratory animals
   - Need for small animal and non-human primate models for diseases caused by *Arenavirus*, *Bunyavirus*, or *Filovirus*
   - Capability to generate animal model data including facilities to handle animals and pathogens

JPM-TMT Funding Profile FY13-17
(Based on FY13 President's Budget)

Adv Dev $K	FY13	FY14	FY15	FY16	FY17	TOTAL
TOTAL	$79,127	$129,775	$112,571	$89,669	$86,761	$497,903

JPM-TMT Points of Contact

Learn how we partner with industry, other government agencies and academia
www.jpmtmt.mil

FOLLOW US ON @JPMTMT AND LIKE US ON

Use your smartphone to scan our QR code and go directly to our website.